Calidi Biotherapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
CLDI$0.68-6.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | ||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(8,268) | $(10,823) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 864 | 801 |
| Stock-based compensation | 388 | 1,129 |
| Change in fair value of other liabilities and derivatives | (47) | (16) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (327) | (156) |
| Accounts receivable | 15 | — |
| Accounts payable | 306 | (733) |
| Accrued expenses and other current liabilities | (733) | (1,449) |
| Operating lease right of use liability | (667) | (764) |
| Net cash used in operating activities | (8,469) | (12,011) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchases of machinery and equipment | (38) | (64) |
| Net cash used in investing activities | (38) | (64) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from public offerings | 5,369 | 3,793 |
| Proceeds from at the market offering | 1,989 | 2,780 |
| Proceeds from exercise of pre-funded warrants | 10 | 3 |
| Repayment of principal on related party term notes payable | — | (1,625) |
| Payment of financing costs | (289) | (381) |
| Proceeds from registered direct offering | — | 3,503 |
| Repayment of principal on term notes payable | — | (200) |
| Repayment of principal on related party bridge loan payable | — | (200) |
| Repayment of financing lease obligations | (91) | (34) |
| Net cash provided by financing activities | 6,988 | 7,639 |
| Effect of exchange rate changes on cash | (10) | 6 |
| NET DECREASE IN CASH AND RESTRICTED CASH | (1,529) | (4,430) |
| CASH AND RESTRICTED CASH BALANCE: | ||
| At beginning of the period | 5,819 | 9,809 |
| At end of the period | $4,290 | $5,379 |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | ||
| Cash paid for interest | $107 | $837 |
| Cash paid for income taxes | $4 | $7 |
| SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES | ||
| Deemed dividend on warrants | $309 | $— |
| Financing fees included in accounts payable and accrued liabilities | $98 | $— |
| Machinery and equipment acquired through financing leases | $141 | $152 |
| Proceeds receivable from at the market offering | $269 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.